https://www.pharmaradar360.com/article/db62ddab8e003ac1PharmaRadar360en2026-04-17T11:49:00.000ZEuropean Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Seasonhttps://www.pharmaradar360.com/article/d8c4b40e3578f832PharmaRadar360en2026-04-17T09:54:25.000ZΚύρια σημεία συνεδρίασης της Επιτροπής Αξιολόγησης Κινδύνου Φαρμακοεπαγρύπνησης (PRAC), 7 – 10 Απριλίου 2026https://www.pharmaradar360.com/article/a19ff0bb7ec5a11cPharmaRadar360en2026-04-17T09:11:51.000ZAspen Australia participates in the 2026 APP Conferencehttps://www.pharmaradar360.com/article/83d3c5118f9af212PharmaRadar360en2026-04-17T07:44:47.000ZDispositifs médicaux et dispositifs médicaux de diagnostic in vitro : un arbre décisionnel pour aider les acteurs concernés par l’article 10bis des règlements européenshttps://www.pharmaradar360.com/article/2294f21f07d72e1cPharmaRadar360en2026-04-17T07:41:34.000Zเตรียมตัวพบกับ! งานบ้านและสวนแฟร์ ขอนแก่น บ้านเฮามักม่วน 2026https://www.pharmaradar360.com/article/206551bd14516dc7PharmaRadar360en2026-04-17T07:28:17.000Zอมรินทร์เปิดเวทีค้นหา “นักพัฒนาชุมชนพอเพียงรุ่นใหม่”https://www.pharmaradar360.com/article/823ce2006bfd78eePharmaRadar360en2026-04-17T07:20:10.000ZΑνάκληση του συμπληρώματος διατροφής MemoVigor2, δισκία, με αρ. παρτίδας Ι015 και ημερομηνία λήξης 02/2027https://www.pharmaradar360.com/article/a6a1b0a875b85061PharmaRadar360en2026-04-17T06:00:00.000ZOtsuka Pharmaceutical Receives Judges' Special Award at MAFF's 10th Shokuiku Activity Awards "MoguMogu Town" App Recognized for Promoting Food and Nutrition Educationhttps://www.pharmaradar360.com/article/a575e8ea4849f5e4PharmaRadar360en2026-04-17T00:00:00.000ZSanten China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Products in the Chinese Mainlandhttps://www.pharmaradar360.com/article/764269c836e855a5PharmaRadar360en2026-04-17T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/42de297ba1def77bPharmaRadar360en2026-04-17T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/ee36e7521659db5dPharmaRadar360en2026-04-17T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/d6f0c471d803f9edPharmaRadar360en2026-04-17T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/37b6cb84d222f020PharmaRadar360en2026-04-17T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/49a858db4ca096faPharmaRadar360en2026-04-17T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/6f106eb05783cda7PharmaRadar360en2026-04-17T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/8d5e69e551da9d1cPharmaRadar360en2026-04-17T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/1c791584877e4df8PharmaRadar360en2026-04-17T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/eb97d02acc1970bfPharmaRadar360en2026-04-17T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/83c9c968a95cc378PharmaRadar360en2026-04-17T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/58d08a610a5e9c45PharmaRadar360en2026-04-17T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/bb0589414f518385PharmaRadar360en2026-04-17T00:00:00.000Z6203https://www.pharmaradar360.com/article/274e5c403a5a167bPharmaRadar360en2026-04-17T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/d494831537d6d5eePharmaRadar360en2026-04-16T16:29:00.000ZOral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability Without Reactive Metabolites or Metabolic/Safety Liability In Vitro or In Vivohttps://www.pharmaradar360.com/article/7fff93584470c64bPharmaRadar360en2026-04-16T16:00:00.000ZHHS budget hearing not so much about budgethttps://www.pharmaradar360.com/article/5ed9e5f525ba38d7PharmaRadar360en2026-04-16T13:00:00.000ZCSPC’s SYS-6051 cleared for clinic in China for solid tumorshttps://www.pharmaradar360.com/article/81d92746e94c6162PharmaRadar360en2026-04-16T13:00:00.000ZChina’s NMPA accepts Mabwell’s IND application for 6MW5311https://www.pharmaradar360.com/article/4b619811c8e94f8cPharmaRadar360en2026-04-16T12:46:36.000ZTulipe et le Snitem signent un partenariat pour renforcer la mobilisation des industries de santé dans l’aide médicale humanitairehttps://www.pharmaradar360.com/article/450d8618e024178cPharmaRadar360en2026-04-16T11:00:00.000ZTiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function